Idiopathic Membranous Nephropathy (IMN) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Idiopathic Membranous Nephropathy (IMN) Emerging Therapy and TPP Insights

Thelansis's "Idiopathic Membranous Nephropathy (IMN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Membranous Nephropathy (IMN) Overview

Idiopathic membranous nephropathy (IMN) is a chronic autoimmune glomerular disease and a leading cause of nephrotic syndrome in adults, characterized by immune complex deposition along the glomerular basement membrane leading to podocyte injury and impaired renal filtration function. The disease is primarily mediated by autoantibodies against phospholipase A2 receptor (PLA2R), which are detected in the majority of patients, while additional antigens such as THSD7A account for a smaller subset of cases.

Patients typically present with nephrotic syndrome, including heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia, with significant risk of thromboembolic events and progressive chronic kidney disease. Diagnosis is based on renal biopsy findings together with serological detection of anti-PLA2R antibodies, which also serve as important biomarkers for disease activity and treatment monitoring.

Management initially focuses on supportive therapy including RAAS blockade, blood pressure control, lipid management, and anticoagulation where appropriate. Rituximab has emerged as the preferred first-line immunosuppressive therapy due to its favorable efficacy and safety profile compared with traditional cyclophosphamide-based regimens and calcineurin inhibitors. Emerging anti-CD20 therapies and precision immunologic approaches are further expanding treatment options for refractory or relapsing disease. Despite therapeutic advances, disease relapse, treatment resistance, and progression to chronic kidney disease continue to represent major clinical challenges.

Key Highlights

• IMN remains one of the leading causes of adult nephrotic syndrome and is strongly associated with anti-PLA2R autoantibodies.
• Progressive proteinuria and chronic kidney disease continue to contribute significantly to long-term renal morbidity.
• Rituximab has increasingly become the preferred first-line immunosuppressive therapy in moderate-to-high-risk disease.
• Emerging anti-CD20 therapies and biomarker-guided treatment strategies are expanding treatment options in refractory disease.
• Increasing adoption of precision nephrology and antibody-guided disease monitoring is improving long-term disease management.

Market Overview

• The global IMN market is expected to witness steady expansion driven by increasing diagnosis rates, biomarker-based testing, and growing adoption of targeted immunotherapies.
• IMN market is projected to reach nearly USD 1 billion by 2035, supported by the launch of emerging targeted therapies and improved disease identification.
• Market growth is supported by:
• Rising utilization of rituximab and emerging B-cell-targeted therapies
• Increasing use of biomarker-guided disease monitoring and personalized treatment strategies
• Expanding clinical development of anti-CD20 and novel immunomodulatory therapies
• Future market growth will depend on next-generation precision therapies, improved relapse prevention strategies, and advancements in targeted autoimmune kidney disease management.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned